• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:ES2566973T9
    申请号:ES10177951.0T
    申请日:2005-03-14
    公开日:2017-01-03
    发明作者:Daniel C. Adelman；Jeffrey A. Silverman；Higaki Masaru；Nakao Satoshi
    申请人:Sumitomo Dainippon Pharma Co Ltd；Sunesis Pharmaceuticals Inc；
    IPC主号:
    专利说明:

    image 1
    image2
    image3
    image4
    image5


    Solution includes the following to prepare a 100 mg / 10 mL presentation: 100 mg of SNS-595 and 450 mg of Dsorbitol are added to distilled water; the volume is brought to a volume of 10 mL; and the pH of the resulting solution is adjusted to 2.5 with methanesulfonic acid. The resulting composition is also suitable for lyophilization. The lyophilized form is then reconstituted with sterile water to the appropriate concentration before use.
    5 Example 2
    Pharmacokinetics of SNS-595 in cancer patients
    SNS-595 was administered to patients included in up to six cycles. A cycle is defined as a three-week period, administering SNS-595 on the first day of each cycle (day 0), followed by at least 21 days of observation. SNS595 was administered to cohorts of at least 3 patients and dose escalation was performed by cohorts consecu
    10 tives The doses of SNS-595 were linear with AUC∞ and their pharmacokinetic properties were remarkably constant among patients of the same cohort. Figure 1 represents the plasma concentrations of SNS595 in relation to the time between the various patient cohorts and Table 1 shows the pharmacokinetic parameters derived from them.
    Table 1
    Dose, mg / m2 Hl hoursCO ng / mLCmax ng / mLLast AUC h-1ng / mLAUC INF_ obs h-1ng / mLCL_obs mL / min / kgVz_obs L / kgVss_ obs L / kgMRTINF_obs h
    3 16.27152.25138.80750.081139.551.141.551.4421.96
    S.D 4,87182,28280,56887,6222630.3180.2970.2776,836
    6 20.69379.69347.002400.002890.290.711.981.2429.05
    S.D 0,327243,598214.96170,556245.640.1530.2950.2181.15
    12 17.812888.602246.675395.536329.150.761.171.0723.67
    S.D 3,8961302.711065,145292,281181,8040.1260.2580.1845,021
    24 16.142884,7022703.3311133.0312655.320.831.151.0621.65
    S.D 2,601189,8772573.02488,453851,4580.1080.1240.1655,261
    48 21.321964.522868.0021098.5327347.360.991.571.4628.90
    S.D 6.32189,8772379,8999405,34614372,7870.6180.5670.478.91
    60 17.634797.474537.5928112.1733616.180.831.201.0823.71
    S.D 4.151947.891947.899127.1213081.440.3520.370.2186.93
    7
    权利要求:
    Claims (1)
    [1]
    image 1
    类似技术:
    公开号 | 公开日 | 专利标题
    ES2566973T9|2017-01-03|Use of SNS-595 to treat leukemia
    CY1111159T1|2015-06-11|CONCENTRATED Methotrexate Solutions
    NO335264B1|2014-10-27|Glucopyranosyl-substituted benzene derivatives, process for their preparation, physiologically acceptable salts of such compounds, drugs containing such compounds and combinations with other active substances, and their use in the manufacture of medicaments for the treatment of disease
    AR045595A1|2005-11-02|USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS
    BR112020014151A2|2020-12-08|BENZAMIDE COMPOUNDS
    AR042977A1|2005-07-13|PALONOSETRON LIQUID PHARMACEUTICAL FORMULATIONS
    AR024060A1|2002-09-04|NEW PHARMACEUTICALLY ACTIVE COMPOUNDS
    ECSP088974A|2009-01-30|IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN |
    AR050918A1|2006-12-06|SOLUTION FOR INFUSION OF DIHYDROPTERIDINONES STABILIZED FOR STORAGE
    ES2553179T3|2015-12-04|Preparation of a lotion containing a pyridoncarboxylic acid derivative
    AR043259A1|2005-07-20|METHOD FOR THE TREATMENT OF SEVERE CARDIAC INSUFFICIENCY AND MEDICATION FOR IT
    AR052198A1|2007-03-07|ANTI-BETA ANTIBODY FORMULATIONS
    CO6160321A2|2010-05-20|USE OF 2-6- | -3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PYRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILE
    NO20065904L|2007-02-20|Therapeutic compounds
    AR037517A1|2004-11-17|DERIVATIVES OF NAFTIRIDINES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AN INFLAMMATORY DISEASE
    EA013973B1|2010-08-30|Methods for treating cutaneous lupus using aminoisoindoline compounds
    AR037629A1|2004-11-17|PHARMACEUTICAL FORMULATIONS THAT INCLUDE A PLATINUM DERIVATIVE
    AR053845A1|2007-05-23|5-TIAZOLILMETIL [| -3 - [[| SULFONIL)] | AMINO] -2-HYDROXY-1- | PROPIL] CARBAMATE AS A PHARMACY IMPROVER METABOLIZED BY THE CYCROCHROME P450
    UY28356A1|2005-01-31|DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATIONS OF THE SAME AND ITS USES
    ES2603570T3|2017-02-28|Colonoscopy Preparation
    AR078224A1|2011-10-26|COMPOSITION FOR THE TREATMENT OF PROSTATE CANCER
    PE20050189A1|2005-05-22|COMPOSITIONS INCLUDING QUINOLONCARBOXYL ACID DERIVATIVES FOR LOCAL ADMINISTRATION
    UY28357A1|2005-01-31|DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION OF THE SAME AND ITS USES
    ES2634026T3|2017-09-26|Medicinal compositions
    MX2009010165A|2009-10-12|New imidazo[ 4,5-b]pyridine-7-carboxamides 704.
    同族专利:
    公开号 | 公开日
    CY1109741T1|2014-09-10|
    JP5317472B2|2013-10-16|
    ES2358267T3|2011-05-09|
    PL1729770T3|2010-05-31|
    US20060063795A1|2006-03-23|
    DK2295056T5|2016-11-28|
    US20180316309A1|2018-11-01|
    US20050215583A1|2005-09-29|
    CA2954578A1|2005-09-29|
    CA2559650C|2013-11-19|
    US8822493B2|2014-09-02|
    US20050203120A1|2005-09-15|
    SI1725233T1|2011-04-29|
    CY1111263T1|2015-08-05|
    NO20161867A1|2006-10-12|
    AT493982T|2011-01-15|
    US8669270B2|2014-03-11|
    CN103251589B|2015-09-30|
    CN1997368B|2014-10-22|
    EP1725233A4|2009-05-20|
    CN103083316A|2013-05-08|
    CA2559652C|2017-02-14|
    EP2295056A1|2011-03-16|
    IL177946A|2016-10-31|
    DK2295056T3|2016-04-11|
    US20060247267A1|2006-11-02|
    EP3053579A1|2016-08-10|
    HK1097196A1|2007-06-22|
    AT451924T|2010-01-15|
    US9757363B2|2017-09-12|
    JP5856644B2|2016-02-10|
    AU2005222622A1|2005-09-29|
    DE602005025738D1|2011-02-17|
    MXPA06010382A|2007-04-23|
    AU2005222607B2|2010-11-25|
    US20130244967A1|2013-09-19|
    JP2007529524A|2007-10-25|
    ZA200607248B|2009-02-25|
    NZ588060A|2011-09-30|
    US7968565B2|2011-06-28|
    JP5096913B2|2012-12-12|
    ES2566973T3|2016-04-18|
    NZ549557A|2010-10-29|
    EP1729770A4|2007-04-11|
    US20160361302A1|2016-12-15|
    NO20064647L|2006-10-12|
    BRPI0508700A|2007-08-07|
    HUE027266T2|2016-10-28|
    JP2017095471A|2017-06-01|
    CN103251589A|2013-08-21|
    CN103083316B|2015-09-30|
    AU2005222607A1|2005-09-29|
    US20110312988A1|2011-12-22|
    US7829577B2|2010-11-09|
    JP2015017110A|2015-01-29|
    EP1729770B1|2009-12-16|
    CN104324029A|2015-02-04|
    CA2559650A1|2005-09-29|
    AU2011201277B2|2012-11-29|
    NO339613B1|2017-01-16|
    DK1725233T3|2011-03-14|
    JP6261477B2|2018-01-17|
    AU2005222622B2|2011-04-07|
    NO20150466L|2006-10-12|
    JP2018119977A|2018-08-02|
    EP1725233A1|2006-11-29|
    US20150190381A1|2015-07-09|
    KR20070033966A|2007-03-27|
    IL248049D0|2016-11-30|
    SI1729770T1|2010-02-26|
    US20170373636A9|2017-12-28|
    JP2014148535A|2014-08-21|
    EP1725233B1|2011-01-05|
    PL2295056T3|2016-07-29|
    CN1997368A|2007-07-11|
    PL1725233T3|2011-05-31|
    JP2011225590A|2011-11-10|
    JP2015227351A|2015-12-17|
    ES2334802T3|2010-03-16|
    JP2007529528A|2007-10-25|
    KR101169825B1|2012-07-30|
    US20060025437A1|2006-02-02|
    WO2005089756A1|2005-09-29|
    EP2295056B9|2016-09-28|
    JP6352863B2|2018-07-04|
    PT1725233E|2011-03-23|
    EP1729770A1|2006-12-13|
    PT1729770E|2010-02-08|
    US20110263524A1|2011-10-27|
    US9980949B2|2018-05-29|
    DK1729770T3|2010-04-12|
    JP2012140442A|2012-07-26|
    IL177946D0|2007-03-08|
    CA2559652A1|2005-09-29|
    CN101703508A|2010-05-12|
    DE602005018333D1|2010-01-28|
    US20140378505A1|2014-12-25|
    WO2005089757A1|2005-09-29|
    AU2011201277A1|2011-04-07|
    EP2295056B1|2016-01-06|
    US7989468B2|2011-08-02|
    NO338058B1|2016-07-25|
    MX349188B|2017-07-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3021A|1843-03-30|Stove with elevated ovejst |
    US216316A|1879-06-10|Improvement in latches |
    US4261989A|1979-02-19|1981-04-14|Kaken Chemical Co. Ltd.|Geldanamycin derivatives and antitumor drug|
    US5078996A|1985-08-16|1992-01-07|Immunex Corporation|Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor|
    NZ287139A|1994-06-14|1997-07-27|Dainippon Pharmaceutical Co|Naphthyridine derivatives; preparative process and anti-tumour medicaments|
    JP4323574B2|1995-12-13|2009-09-02|大日本住友製薬株式会社|Antitumor agent|
    ES2197453T3|1997-01-13|2004-01-01|Kudos Pharmaceuticals Limited|TESTS, AGENTS, THERAPY AND DIAGNOSIS RELATED TO THE MODULATION OF CELLULAR DNA REPAIR ACTIVITY.|
    US20020032216A1|1997-03-21|2002-03-14|Lg Chemical Ltd.|Salt of naphthyridine carboxylic acid derivative|
    CA2293724C|1997-06-05|2010-02-02|Xiaodong Wang|Apaf-1, the ced-4 human homolog, an activator of caspase-3|
    US6171857B1|1997-10-17|2001-01-09|Brown University Research Foundatiion|Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity|
    US5968921A|1997-10-24|1999-10-19|Orgegon Health Sciences University|Compositions and methods for promoting nerve regeneration|
    IL124015D0|1998-04-08|1999-01-26|Yeda Res & Dev|Pharmaceutical compositions comprising a protein|
    JP4294121B2|1998-06-05|2009-07-08|大日本住友製薬株式会社|Process for producing pyridonecarboxylic acid derivatives and intermediates thereof|
    EP1090146B1|1998-06-30|2007-05-23|Sloan-Kettering Institute For Cancer Research|Uses of dna-pk|
    US6670144B1|1999-02-26|2003-12-30|Cyclacel, Ltd.|Compositions and methods for monitoring the phosphorylation of natural binding partners|
    CA2363621A1|1999-02-26|2000-08-31|The Johns Hopkins University|A novel inhibitor of programmed cell death|
    US7163801B2|1999-09-01|2007-01-16|The Burnham Institute|Methods for determining the prognosis for cancer patients using tucan|
    US6479541B1|2000-03-30|2002-11-12|Baxter International|Amiodarone-containing parenteral administration|
    JP2004500849A|2000-05-20|2004-01-15|キャンサー・リサーチ・テクノロジー・リミテッド|Drug screening systems and assays|
    US7179912B2|2000-09-01|2007-02-20|Icos Corporation|Materials and methods to potentiate cancer treatment|
    US6696483B2|2000-10-03|2004-02-24|Oncopharmaceutical, Inc.|Inhibitors of angiogenesis and tumor growth for local and systemic administration|
    EP1337275A4|2000-11-02|2007-05-09|Sloan Kettering Inst Cancer|Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors|
    US20050158724A1|2002-04-05|2005-07-21|Fishel Richard A.|Methods, of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof|
    EP1660473A2|2003-03-24|2006-05-31|Luitpold Pharmaceuticals, Inc.|Xanthones, thioxanthones and acridinones as dna-pk inhibitors|
    PL2295056T3|2004-03-15|2016-07-29|Sunesis Pharmaceuticals Inc|Use of SNS-595 for treating leukemia|
    AU2006287149B2|2005-09-02|2013-05-23|Sunesis Pharmaceuticals, Inc.|Methods of using -1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid for treatment of cancer|
    US8580814B2|2006-04-03|2013-11-12|Sunesis Pharmaceuticals, Inc.|Methods of using -1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4- oxo-1--1,8-naphthyridine-3-carboxylic acid for treatment of cancer|
    CN104027333B|2006-06-12|2017-05-17|逊尼希思制药公司|Compounds And Compositions For Treatment Of Cancer|
    WO2008016678A2|2006-08-01|2008-02-07|Sunesis Pharmaceuticals, Inc.|Pharmaceutical dosage forms for -1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid|
    JP2009545601A|2006-08-02|2009-12-24|サネシスファーマシューティカルズ，インコーポレイテッド|-1,4-dihydro-7-[ -3-methoxy-4- -1-pyrrolidinyl] -4-oxo-1- -1,8 -Combination use of naphthyridine-3-carboxylic acid|
    EP2214662B1|2007-10-22|2016-07-13|Sunesis Pharmaceuticals, Inc.|-1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer|
    CA2708264C|2007-12-10|2018-07-03|Sunesis Pharmaceuticals, Inc.|Methods of using -1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders|
    AU2009335159B2|2008-12-31|2015-07-23|Sunesis Pharmaceuticals, Inc.|Method of preparing -1,4-dihydro-7-[-3methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid|
    EP2400959A1|2009-02-27|2012-01-04|Sunesis Pharmaceuticals, Inc.|Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity|
    CN101631081B|2009-08-12|2011-06-08|华为技术有限公司|Multistage switched network|
    SG178956A1|2009-09-04|2012-04-27|Sunesis Pharmaceuticals Inc|Stable sns-595 compositions and methods of preparation|
    US8470817B2|2009-10-26|2013-06-25|Sunesis Pharmaceuticals, Inc.|Compounds and methods for treatment of cancer|AU2006287149B2|2005-09-02|2013-05-23|Sunesis Pharmaceuticals, Inc.|Methods of using -1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid for treatment of cancer|
    PL2295056T3|2004-03-15|2016-07-29|Sunesis Pharmaceuticals Inc|Use of SNS-595 for treating leukemia|
    US7652134B2|2004-09-17|2010-01-26|Cylene Pharmaceuticals, Inc.|Methods for converting quinolone esters into quinolone amides|
    CA2580749C|2004-09-17|2014-01-28|Cylene Pharmaceuticals, Inc.|Quinolone analogs|
    WO2007022474A2|2005-08-19|2007-02-22|Cylene Pharmaceuticals, Inc.|HUMAN RIBOSOMAL DNA AND RIBOSOMAL RNANUCLEIC ACIDS AND USES THEREOF|
    US8580814B2|2006-04-03|2013-11-12|Sunesis Pharmaceuticals, Inc.|Methods of using -1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4- oxo-1--1,8-naphthyridine-3-carboxylic acid for treatment of cancer|
    CA2620915C|2005-09-02|2014-03-25|Sunesis Pharmaceuticals, Inc.|Methods of using -1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid for treatment of cancer|
    CN104027333B|2006-06-12|2017-05-17|逊尼希思制药公司|Compounds And Compositions For Treatment Of Cancer|
    WO2008016678A2|2006-08-01|2008-02-07|Sunesis Pharmaceuticals, Inc.|Pharmaceutical dosage forms for -1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid|
    JP2009545601A|2006-08-02|2009-12-24|サネシスファーマシューティカルズ，インコーポレイテッド|-1,4-dihydro-7-[ -3-methoxy-4--1-pyrrolidinyl] -4-oxo-1--1,8 -Combination use of naphthyridine-3-carboxylic acid|
    AU2008310883A1|2007-10-09|2009-04-16|Hamann, Mark T|Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter|
    AU2014277779B2|2007-10-22|2016-05-19|Sunesis Pharmaceuticals, Inc.|METHODS OF USING -1,4-DIHYDRO-7-[-3-METHOXY-4--1-PYRROLIDINYL]-4-OXO-1--1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY|
    EP2214662B1|2007-10-22|2016-07-13|Sunesis Pharmaceuticals, Inc.|-1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer|
    CA2708264C|2007-12-10|2018-07-03|Sunesis Pharmaceuticals, Inc.|Methods of using -1,4-dihydro-7-[-3-methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders|
    AU2009335159B2|2008-12-31|2015-07-23|Sunesis Pharmaceuticals, Inc.|Method of preparing -1,4-dihydro-7-[-3methoxy-4--1-pyrrolidinyl]-4-oxo-1--1,8-naphthyridine-3-carboxylic acid|
    EP2400959A1|2009-02-27|2012-01-04|Sunesis Pharmaceuticals, Inc.|Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity|
    SG178956A1|2009-09-04|2012-04-27|Sunesis Pharmaceuticals Inc|Stable sns-595 compositions and methods of preparation|
    US8470817B2|2009-10-26|2013-06-25|Sunesis Pharmaceuticals, Inc.|Compounds and methods for treatment of cancer|
    EP2819498B1|2012-02-27|2017-02-15|AGQ Technological Corporate S.A.|Monitoring and control of soil conditions|
    RS61664B1|2012-04-24|2021-04-29|Vertex Pharma|Dna-pk inhibitors|
    PT2970218T|2013-03-12|2019-03-01|Vertex Pharma|Dna-pk inhibitors|
    US20160067182A1|2013-04-09|2016-03-10|Merrimack Pharmaceuticals, Inc.|Methods and compositions for improving outcomes of liposomal chemotherapy|
    EP3016659A4|2013-07-02|2017-03-15|Eustralis Pharmaceuticals Limited |Method for preventing and/or treating chronic traumatic encephalopathy-iii|
    AU2014337154B2|2013-10-17|2018-06-28|Vertex Pharmaceuticals Incorporated|Co-crystals of -N-methyl-8-amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as DNA-PK inhibitors|
    KR101775356B1|2015-07-06|2017-09-06|재단법인 아산사회복지재단|Method for Determining Susceptibility to Dual Inhibitor against PARP and Tankyrase|
    TW201815418A|2016-09-27|2018-05-01|Vertex Pharma|Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US55357804P| true| 2004-03-15|2004-03-15|
    US553578P|2004-03-15|
    [返回顶部]